Evidence map›Paper›PMID 35835905›Full record

ArticleNature communications2022

Cell-autonomous Hedgehog signaling controls Th17 polarization and pathogenicity.

Joachim Hanna, Flavio Beke, Louise M O'Brien, Chrysa Kapeni, Hung-Chang Chen, Valentina Carbonaro, Alexander B Kim, Kamal Kishore, Timon E Adolph, Mikkel-Ole Skjoedt and 3 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. L-type voltage-gated CaEMBO reports · 2026
    Article
  3. Review
  4. Review
  5. Mechanism of action of IHH in ameliorating thin endometrium.The Journal of reproduction and development · 2025
    Article
  6. Review
  7. Signaling pathways and advances in targeted therapy for adenomyosis.Frontiers in cell and developmental biology · 2025
    Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 3 countries.

Joachim HannaCancer Research UK Cambridge Institute, University of Cambridge, Robinson Way, Cambridge, CB2 0RE, UK.ORCID 0000-0002-2055-1462
Flavio BekeCancer Research UK Cambridge Institute, University of Cambridge, Robinson Way, Cambridge, CB2 0RE, UK.ORCID 0000-0002-2294-0306
Louise M O'BrienCancer Research UK Cambridge Institute, University of Cambridge, Robinson Way, Cambridge, CB2 0RE, UK.ORCID 0000-0002-8121-5374
Chrysa KapeniCancer Research UK Cambridge Institute, University of Cambridge, Robinson Way, Cambridge, CB2 0RE, UK.ORCID 0000-0003-0408-2106
Hung-Chang ChenCancer Research UK Cambridge Institute, University of Cambridge, Robinson Way, Cambridge, CB2 0RE, UK.ORCID 0000-0002-2849-6752
Valentina CarbonaroCancer Research UK Cambridge Institute, University of Cambridge, Robinson Way, Cambridge, CB2 0RE, UK.
Alexander B KimCancer Research UK Cambridge Institute, University of Cambridge, Robinson Way, Cambridge, CB2 0RE, UK.ORCID 0000-0002-6425-4566
Kamal KishoreCancer Research UK Cambridge Institute, University of Cambridge, Robinson Way, Cambridge, CB2 0RE, UK.ORCID 0000-0002-4650-8745
Timon E AdolphDepartment of Internal Medicine I, Gastroenterology, Hepatology & Endocrinology, Medical University Innsbruck, Innsbruck, Austria.ORCID 0000-0002-4736-830X
Mikkel-Ole SkjoedtRigshospitalet - University Hospital Copenhagen, Blegdamsvej 9, 2100, Copenhagen, Denmark.
Karsten SkjoedtUniversity of Southern Denmark, J.B.Winslows Vej, 5000, Odense C, Denmark.
Marc de la RocheDepartment of Biochemistry, University of Cambridge, 80 Tennis Court Road, Cambridge, CB2 1GA, UK.
Maike de la RocheCancer Research UK Cambridge Institute, University of Cambridge, Robinson Way, Cambridge, CB2 0RE, UK. maike.delaroche@cruk.cam.ac.uk.ORCID 0000-0002-0558-4119
University of Cambridge · GBInnsbruck Medical University · ATUniversity of Copenhagen · DKUniversity of Southern Denmark · DK

Funding

Austrian Science Fund FWF P 29379Austrian Science Fund FWF P 33070Cancer Research UK 22257Cancer Research UK A22257Medical Research Council 1954837Wellcome Trust WT107609
6 · The paper itself

Abstract

Th17 cells are key drivers of autoimmune disease. However, the signaling pathways regulating Th17 polarization are poorly understood. Hedgehog signaling regulates cell fate decisions during embryogenesis and adult tissue patterning. Here we find that cell-autonomous Hedgehog signaling, independent of exogenous ligands, selectively drives the polarization of Th17 cells but not other T helper cell subsets. We show that endogenous Hedgehog ligand, Ihh, signals to activate both canonical and non-canonical Hedgehog pathways through Gli3 and AMPK. We demonstrate that Hedgehog pathway inhibition with either the clinically-approved small molecule inhibitor vismodegib or genetic ablation of Ihh in CD4

Indexed as

Colitis, UlcerativeTh17 CellsAdultAnimalsHedgehog ProteinsHumansMiceSignal TransductionVirulenceHedgehog Proteins

Identifiers

PMID35835905
PMCPMC9281293
OpenAlexW4285389756

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.